TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04038255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two brief follow-up phone calls
Description: The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MT sessions
Description: Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice on quitting smoking
Description: Standard advice on how to quit smoking.
Study: NCT01193777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bolus followed by 1 L NS infusion over 12 hours.
Study: NCT04038255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help smoking cessation materials
Description: Written materials on how to quit smoking including contact info for state tobacco quitline.
Study: NCT04990453

Intervention type: OTHER
Group type: OTHER
Intervention: RPD frameworks fabricated from PEEK material
Description: extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)

Intervention type: OTHER
Group type: OTHER
Intervention: RPD frameworks fabricated from PEEK material
Description: extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
Study: NCT03870061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Babies Are Equal Initiative (conditional cash transfer program)
Description: New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
Study: NCT01626794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™ VEP
Description: Two 0.5 mL subcutaneous doses administered on Days 1 and 91

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™ 2007 Process
Description: Two 0.5 mL subcutaneous doses administered on Days 1 and 91

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R™ II
Description: Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
Study: NCT02815189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ibuprofen for post operative pain
Description: All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ibuprofen for post operative pain
Description: All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 325 mg for Flare up
Description: Each patient will be evaluated a week after completion the clinical procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 325 mg for Flare up
Description: Each patient will be evaluated a week after completion the clinical procedures.
Study: NCT04130009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet use
Description: Use of Tourniquet in The TKA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet use
Description: Use of Tourniquet in The TKA
Study: NCT01576731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir, Emtricitabine, Lopinavir/r
Description: Combination drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir, Emtricitabine, Raltegravir
Description: Combination drug
Study: NCT01972607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
Study: NCT04188860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
Description: A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
Study: NCT04205643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC (Infliximab)
Description: Subcutaneous injection of CT-P13 SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Subcutaneous injection of Placebo SC
Study: NCT00987337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filibuvir
Description: 300 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filibuvir
Description: 600 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study: NCT02630251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2820151
Description: GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
Study: NCT02416063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Dexmedetomidine
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexmedetomidine
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia
Study: NCT04113161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child Behavioral Health Navigator (cbhN)
Description: CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
Study: NCT02345980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02578043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%
Description: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onexton™ Gel
Description: Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT06538428

Intervention type: GENETIC
Intervention: DNA methylation profiling
Description: measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene

Intervention type: GENETIC
Intervention: DNA methylation profiling
Description: measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
Study: NCT03542500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI)
Description: The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrepreneurship Training
Description: The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrepreneurship Training
Description: The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
Study: NCT03356431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Description: * Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: * Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec.
Study: NCT01138852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-sulbactam
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
Study: NCT03985319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYD601 20mg
Description: Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium tab 20mg
Description: Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
Study: NCT04027660

Intervention type: DEVICE
Intervention: Immediate Zirconia Dental Implant
Description: For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements
Study: NCT05269524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered tailored cognitive behavior therapy
Description: Therapists-supported tailored 10-week treatment for depression in older adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered tailored cognitive behavior therapy
Description: Therapists-supported tailored 10-week treatment for depression in older adults.
Study: NCT02182284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BI 201335 NA soft gelatine capsule (SGC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BI 201335 NA soft gelatine capsule (SGC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BI 201335 NA powder in bottle (PIB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BI 201335 NA powder in bottle (PIB)
Study: NCT05209191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student Athlete Wellness Portal
Description: A web-based design that illustrates various opioid misuse and diversion resistance strategies.
Study: NCT00215293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical I/F Cage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft or allograft with a plate, or autograft alone.
Study: NCT02990663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of blood pressure lowering medication at bedtime
Description: Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of blood pressure lowering medication in the morning
Description: Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
Study: NCT00928317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 3.0mg/kg s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 1.5mg/kg s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 0.75mg/kg s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c.
Study: NCT03766646

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflow
Description: 45l.min oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: 45l.min oxygen
Study: NCT01061060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin I2
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03893227

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients and healthy controls will fill out a questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients and healthy controls will fill out a questionnaire
Study: NCT02591693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver training
Description: Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
Study: NCT00541047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Study: NCT04449354

Intervention type: DEVICE
Group type: OTHER
Intervention: HidraWear Ax
Description: An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
Study: NCT00541047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy